PB Absorbance (490 nm) ± SEM % viability Fold change, with respect to Control TG TG-F             Control 2.321 ± 0.25 100.00       TG24 1.887 ± 0.45 81.30 (-) 1.23     TG24F 2.164 ± 0.37 93.23   (+) 1.15   TG24MF 2.193 ± 0.07 94.48   (+) 1.16 (+) 1.01 TG48 1.725 ± 0.29 74.33 (-) 1.35     TG48F 2.102 ± 0.11 90.58   (+) 1.22   TG48MF 2.317 ± 0.06 99.82   (+) 1.34 (+) 1.10 TG72 1.186 ± 0.32 51.11 (-) 1.96#     TG72F 1.499 ± 0.33 64.61   (+) 1.26   TG72MF 1.466 ± 0.12 63.19   (+) 1.24 (-) 1.02 TG96 0.995 ± 0.21 42.89 (-) 2.33#     TG96F 1.419 ± 0.20 61.13   (+) 1.43   TG96MF 1.215 ± 0.11 52.34   (+) 1.22 (-) 1.17 (#: p<0.05 versus Control; *: p<0.05 versus TG; *: p<0.05 versus TG-F)

Table 8: Fold changes in viability of cells in peripheral blood, assayed by MTS reagent, at 492nm. With fisetin, there is a 1.15 fold increase after 24h, a 1.22 fold increase after 48 h, a 1.26 fold increase after 72 h and a 1.43 fold increase after 96 h. With MCN+fisetin, there is a 1.16 fold increase after 24 h, a 1.34 fold increase after 48 h, a 1.24 fold increase after 72 h and a 1.22 fold (p<0.05) increase after 96 h.